NasdaqHealth CareHealth Care EquipmentS&P SmallCap 600
$80.89
-2.60 (-3.11%)
Close of Nov 06, 2026 · end-of-day data
LMAT 8-K filings in 2024
Every material Form 8-K LeMaitre Vascular filed with the SEC in 2024, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
LeMaitre Vascular issued $172.5 million of 2.50% convertible senior notes due 2030 on December 19, 2024, including the full $22.5 million option exercised by the initial purchasers. The company says it will use the net proceeds for working capital and general purposes, which may include acquisitions or investments, and the notes add debt that can convert into common stock at about $119.73 per share.
Notes: $172.5 million principal, 2.50% annual interest, maturing February 1, 2030
Initial conversion price of approximately $119.73 per share (8.3521 shares per $1,000 principal)
Company may settle conversions in cash, shares, or a combination; notes redeemable on or after February 5, 2028 under stated conditions
Notes are unsecured senior obligations under an indenture with U.S. Bank Trust Company, National Association, as trustee
LeMaitre Vascular reported preliminary, unaudited results for the quarter ended September 30, 2024, with net sales of $54.8 million, up 16% from a year earlier, and diluted earnings per share of $0.49, up from $0.33. The company also raised its full-year 2024 guidance, which for sales is $219.0 million to $221.0 million and for EPS is $1.91 to $1.96, giving shareholders a higher outlook for growth and profit.
Q3 2024 net sales were $54.8 million, up from $47.4 million in Q3 2023.
Q3 operating income was $13.1 million, up from $9.2 million, and diluted EPS was $0.49 versus $0.33.
Full-year 2024 sales guidance is $219.0 million to $221.0 million, and EPS guidance is $1.91 to $1.96.
The Board approved a $0.16 per share quarterly dividend, payable December 5, 2024, to holders of record on November 21, 2024.
LeMaitre Vascular said Chief Financial Officer Joseph P. Pellegrino Jr. will retire as an employee effective March 7, 2025, after the anticipated filing of the 2024 Form 10-K, and will remain on the Board of Directors. The company will search for a replacement CFO and expects Pellegrino to take part in the hiring process. The company also reaffirmed its August 1, 2024 financial guidance for Q3 and full-year 2024 as of August 26, 2024.
Pellegrino retires as an employee, including as CFO, effective March 7, 2025
He remains on the Board, serving out his term until June 2027 after being re-elected in June 2024
The company thanks him for 19 years of executive service and will search for a replacement CFO
Guidance from August 1, 2024 for Q3 2024 and Full-Year 2024 was reaffirmed as of August 26, 2024
LeMaitre Vascular reported preliminary second-quarter 2024 results, with sales of $55.8 million, up 11% from a year earlier, and net income of $11.8 million, up 46%. The company raised its full-year 2024 guidance, now projecting sales of $216.8 million to $220.8 million and EPS of $1.82 to $1.91, which shareholders will weigh alongside the company's higher quarterly profitability.
Q2 2024 sales $55.8 million, up 11% (12% organic); diluted EPS $0.52, up 44%
Gross margin 68.9%, up from 64.0% in Q2 2023; operating income $14.4 million, up 52%
Full-year 2024 guidance: sales $216.8 million to $220.8 million; EPS $1.82 to $1.91
Quarterly dividend of $0.16 per share payable August 29, 2024, to holders of record August 15, 2024
At its June 3, 2024 annual meeting, LeMaitre Vascular shareholders re-elected or elected three Class III directors, but Lawrence J. Jasinski received 8,277,096 votes for and 11,308,332 withheld. Under the company's governance guidelines he tendered his resignation, but the board rejected it after considering the Nominating and Corporate Governance Committee's recommendation. Shareholders also approved an amended stock option and incentive plan that authorizes 1,000,000 new shares and extends the plan to June 3, 2034.
Jasinski received fewer votes for than against his election; the board rejected his resignation on June 3, 2024
Amended and restated stock option plan approved with 19,332,353 votes for and 411,532 against, adding 1,000,000 shares and running to June 3, 2034
Advisory say-on-pay vote approved with 19,118,371 votes for and 624,991 against
Grant Thornton LLP ratified as independent auditor for the year ending December 31, 2024 (20,642,552 for, 93,844 against)
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every LeMaitre Vascular filing is on SEC EDGAR ↗. 8-K briefs of other companies →